An observational study in COVID-19 Vaccines, sponsored by Mebo Research, Inc.. Active, not recruiting at 5 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-26.
Sponsored by Mebo Research, Inc. · Observational
During the study, members of different online and offline communities will be followed post COVID-19 vaccination.
Injection-site (local) and systemic reaction data will be assessed on vaccination day and afterwards using either web surveys or personal communication, depending on study participant preference.
Hypothesis to be tested: The safety profile and the magnitude and durability of immune responses to the COVID-19 vaccines as well as adverse reactions depend on health conditions, metabolism and microbiomes.
The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a Public Health Emergency of International Concern in January 2020 and upgraded to pandemic in March 2020. First vaccines to prevent COVID-19 were authorized for emergency use in the US in December 2020, but a number of unknowns still remains. One of these unknowns is the relationship of the microbiota, gut dysbiosis and impaired metabolism with active immunity to pathogens and vaccines and tolerance to antigens. Study groups will be based on age, metabolism, donated diagnostic test results and self-reported symptoms. Data will be collected continuously via surveys and investigator-participant interactions, as needed. Statistical methods used will be the ones with the greatest power.
449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.
This study's enrollment of 2,000 is above the median of 414 across 162 observational studies indexed under Drug-Related Side Effects and Adverse Reactions.
Browse Drug-Related Side Effects and Adverse Reactions studies →Mebo Research, Inc. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Individuals 18 or older interested in vaccinating
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals 80-89, 90-99, 100 years of age and older who received COVID-19 vaccine
Biological: COVID-19 vaccines
Individuals 60-69 and 70-79 years of age who received COVID-19 vaccine
Biological: COVID-19 vaccines
Individuals in 40-49, 50-59 age range who received COVID-19 vaccine
Biological: COVID-19 vaccines
Individuals in 18-29, 30-39 age range who received COVID-19 vaccine
Biological: COVID-19 vaccines
Individuals with present or past MEBO/PATM symptoms who received COVID-19 vaccine
Biological: COVID-19 vaccines
Individuals with self-reported chronic health conditions who received COVID-19 vaccine
Biological: COVID-19 vaccines
Emergency-use authorized COVID-19 vaccines
Also known as: BNT162b2, mRNA-1273, JNJ-78436735, AZD1222, Gam-KOVID-Vak, CoronaVac/Sinovac, BBIBP-CorV, BBV152, NVX-CoV2373
Adverse reactions/events
Percentage of occurrence, types, duration and severity of adverse events occurring within 10 days post-doses 1 and 2
Time frame: 10 days after any dose of study intervention.
Long-term adverse events
Percentage of occurrence, types, duration and severity of adverse events throughout study period
Time frame: Throughout the study period, until 12 months post-final-dose
Incidence of COVID-19 cases
The number of COVID-19 cases occurring \<=14 or ≥ 15 days after any dose of study intervention.
Time frame: From 14 days after completion of the 2-dose regimen up to 12 months post-final-dose
Plan to share: No — individual participant data will remain confidential, unless specifically requested to be shared by the participant
This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Drug-Related Side Effects and Adverse Reactions →
Mebo Research, Inc.